NASDAQ:INHX

Inhibitex (INHX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
INHX stock logo

About Inhibitex Stock (NASDAQ:INHX)

Inhibitex, Inc. develops antibody-based products for the treatment and prevention of bacterial and fungal infections. The Company produces products that can be used as vaccines, binding inhibitors or separation supports for affinity purifications. The Company's lead product candidate, Veronate, which entered into Phase III clinical trial in the second half of 2004, is being developed for the prevention of hospital-associated infections in premature, very low birth weight, (VLBW) infants.

INHX Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive INHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibitex and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:INHX
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:INHX) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners